z-logo
Premium
Association between psoriasis and chronic obstructive pulmonary disease: a population‐based study in Taiwan
Author(s) -
Chiang Y.Y.,
Lin H.W.
Publication year - 2012
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2011.04009.x
Subject(s) - medicine , psoriasis , copd , hazard ratio , comorbidity , cohort , population , cohort study , confidence interval , physical therapy , environmental health , immunology
Background  Psoriasis is regarded as a systemic inflammatory disease, having been linked in recent studies, to a wide range of systemic disorders. Previous studies have reported a positive correlation between psoriasis and chronic obstructive pulmonary disease (COPD); however, no studies have been conducted on an ethnic Chinese population. Methods  We conducted a population‐based study, using a representative cohort from the National Health Insurance database in Taiwan, between 2004 and 2006. The risk of COPD was compared between patients with psoriasis and a matched reference cohort. This study included 2096 psoriasis patients and 8384 randomly selected controls. Results  After adjusting for sociodemographic characteristics and selected chronic diseases, the hazard ratio (HR) for COPD in psoriasis patients was 2.35 (95% confidence interval (CI): 1.42–3.89) compared with the control group in 18 months of follow‐4 up. Men (HR = 2.38, 95% CI: 1.36–4.18) and patients with psoriasis over 50 years of age (HR = 2.19, 95% CI: 1.27–3.77) were more likely to contract COPD. Conclusions  We concluded that psoriasis patients were at a greater risk of developing COPD with significantly lower COPD‐free survival rates than the comparison cohort ( P  < 0.001). Physicians should be aware of this potential risk to reduce comorbidity and mortality.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here